Summary: In a biomarker substudy of patients treated with empagliflozin after acute myocardial infarction, the drug altered sirtuin and microRNA expression, and a four-marker molecular panel predicted limited ejection-fraction recovery with high accuracy (AUC 0.890), outperforming baseline NT-proBNP.
PICO Summary
| Element | Detail |
|---|---|
| Population | 227 patients after acute myocardial infarction (biomarker analysis within a randomised trial). |
| Intervention | Empagliflozin for 26 weeks, with sirtuin (SIRT1–7) and microRNA (miR-182-5p, miR-302a-3p) expression measured. |
| Comparison | Placebo over the same 26 weeks, with paired baseline and follow-up assessments. |
| Outcome | Empagliflozin raised SIRT6 and lowered SIRT4. A panel (SIRT2, SIRT4, miR-182-5p, miR-302a-3p) predicted ΔLVEF <11% with AUC 0.890 (81% sensitivity, 90% specificity), significant after adjustment. Baseline NT-proBNP did not predict outcome. |
Expert Commentary
I read this as a mechanistic and prognostic study rather than anything that touches my prescribing, and on those terms it is genuinely interesting. That empagliflozin shifts sirtuin and microRNA expression fits the broader effort to explain why SGLT2 inhibitors help the heart beyond glucose lowering, and a four-marker panel discriminating limited ejection-fraction recovery with an AUC of 0.890, outperforming NT-proBNP, is an encouraging signal. My caution is methodological and firm. This is an observational biomarker analysis, so association is not causation, and a multi-marker panel built in 227 patients without external validation carries a real risk of overfitting, which is precisely how impressive AUCs shrink on replication. The endpoint is also a surrogate, change in ejection fraction, not hospitalisation or death, and the assays are not clinically available. Can I use this with my patients? Not at all in any direct sense. I will keep prescribing empagliflozin on its established post-infarction and heart-failure indications, where the outcome evidence is solid, and treat this panel as a research tool awaiting validation. I would want an external cohort and hard endpoints before it influenced care.
References
Nowak-Szwed A, Eyileten C, Wicik Z, et al. Sirtuins and regulatory miRNAs as epigenetic determinants of empagliflozin-mediated recovery after acute myocardial infarction. Cardiovasc Diabetol. 2025;24(1):463. doi:10.1186/s12933-025-03013-y